Science & Co Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A medication study and a telehealth product page answer different questions. For Science & Co, that distinction matters before comparing either weight-loss claims or advertised monthly prices. The company markets access to compounded semaglutide and tirzepatide injections alongside branded injections and tablets. Its documentation can show what it advertises, how it describes clinical review and what its terms require. It cannot, by itself, establish that patients using this platform achieve the outcomes reported in clinical trials.

This review examines public documentation consulted October 19, 2026, separating contractual statements, commercial claims and independent clinical context. Science & Co describes a nationwide platform connecting adults with independent clinicians and pharmacies—not a company that itself practices medicine or dispenses prescriptions. Its published starting prices are meaningful, but tied to 12-month plans whose initial payment and early-cancellation economics remain unclear. The central evidence question is therefore not simply whether GLP-1 medicines have been studied, but how closely the documented service and actual prescribed product match the evidence a reader is relying on.

At a glance

Platform, not medical practice: Science and Co, Inc. identifies itself as a Delaware corporation operating a telehealth platform; independent professional entities provide care and pharmacies dispense prescriptions.
Sources: [12]
Conditional advertised prices: Compounded semaglutide injection starts at $59 per month and compounded tirzepatide injection at $99 per month on 12-month plans. The consulted documentation does not establish the initial payment.
Sources: [14] [15]
Clinical access: The platform advertises availability for adults in all 50 states and Washington, DC; prescriptions require a consultation, clinician determination and prescription issuance.
Sources: [12]
Compounding claims: Science & Co says it uses state-licensed US compounding pharmacies, third-party tests every batch and makes certificates of analysis available on request. These are provider claims, not independent verification.
Sources: [14]
Cancellation boundary: Pause or cancel at least 72 hours before the next scheduled processing date. Cancellation stops future orders but does not reverse an order already prescribed, dispensed or shipped.
Sources: [14] [9]

Start with the entity behind the promise

Science & Co’s terms identify the operator as Science and Co, Inc., a Delaware corporation. They explicitly say the company is not a medical services provider and does not dispense medications. Instead, healthcare services belong to independent professional entities and their licensed healthcare professionals, while prescription fulfillment belongs to independent pharmacies. That allocation matters: the company’s branding unifies the experience, but the clinical and dispensing responsibilities are not all held by the platform.

The terms advertise services in all 50 states and the District of Columbia, only for people located within the United States. Access requires being at least 18. Those are geographic and age boundaries, not a complete medical eligibility policy. The consulted pages do not identify the professional entity, individual prescriber or dispensing pharmacy that would serve a particular patient. State-specific licensing is asserted by the provider; it was not independently verified for this review.

This is a useful example of what public provider documents can establish: they describe the service model and commitments without proving every operational claim. Before enrollment, a reader can reasonably ask for the names of the treating entity and dispensing pharmacy, plus which organization handles clinical concerns, prescription changes and order problems. Those details would make the advertised division of responsibility more usable than a general assurance about a connected care team.

Sources: [12] [14]

The catalog contains several different evidence questions

Science & Co advertises compounded semaglutide injection and compounded tirzepatide injection, each described as a once-weekly prescription product. A separate personalized GLP-1 and GIP-1 injection page does not identify its precise active ingredient in the quoted product heading. That omission prevents a reader from treating the personalized listing as a clearly specified formulation. The catalog also includes NAD+ and sermorelin injections under longevity; those listings should not be mistaken for evidence about its GLP-1 service.

The branded offerings include Zepbound tirzepatide injection from Eli Lilly and Wegovy semaglutide injection from Novo Nordisk. Science & Co also advertises Wegovy semaglutide tablets and Foundayo orforglipron tablets. For those oral products, the company says the manufacturer’s medicine is dispensed sealed and unaltered by a licensed US pharmacy, is not compounded and is FDA approved. These are provider statements in the consulted pages, not independent confirmation of each product’s regulatory status or availability.

The product distinctions below are more informative than treating the entire catalog as one interchangeable GLP-1 offering. Route, formulation and identifiable ingredients affect which evidence can reasonably be applied. The microdose injection page says “Coming Soon,” so availability is not confirmed despite conflicting catalog labeling. Readers comparing listings should use the same discipline explained in our guide to formulation and route: a shared ingredient name or drug-family label does not resolve every product-specific question.

How to read the advertised product categories
Listing	Documented description	Evidence boundary
Compounded semaglutide	Prescription injection	Not an FDA-approved compounded preparation
Compounded tirzepatide	Prescription injection	Platform claims do not establish clinical equivalence
Personalized GLP-1/GIP-1	Prescription injection	Precise active ingredient is not established
Branded injections and tablets	Named manufacturer products advertised	Product and regulatory statements require product-specific confirmation
GLP-1/GIP-1 Microdose	Injection page says Coming Soon	Availability and provider-specific outcomes are not established

Sources: [14] [15] [16] [7] [10] [11] [13] [8] [6]

What the intake and prescribing process actually promises

The advertised entry point is an online questionnaire taking approximately five minutes, with no commitment at that initial stage. The illustrated intake asks about previous GLP-1 use, type 2 diabetes, thyroid history, and pregnancy or nursing. These questions demonstrate subjects the company says it screens; they do not establish complete inclusion or exclusion rules. The consulted documentation does not specify comprehensive BMI criteria, routine laboratory requirements or how particular answers change the consultation process.

Science & Co says a licensed clinician reviews the answers and that most reviews finish within 24–48 hours. That is an advertised review interval, not a guaranteed prescription, shipment or delivery time. The terms require a completed consultation, a determination that the product is appropriate and an issued prescription before a prescription product is provided. The product page further says nothing is dispensed without clinician approval and each prescription comes from a provider licensed in the patient’s state.

This creates a documented clinical gate rather than an automatic purchase-to-prescription pathway. What remains less clear is the consultation format beyond the questionnaire and review, how additional information is requested, and whether required laboratory testing costs extra. NIDDK describes medication selection as a discussion encompassing health conditions, other medicines, benefits, side effects and cost. That clinical context supports asking how those issues are evaluated here, without assuming that an online form alone establishes the full quality of care.

Sources: [14] [12] [2]

Quality documentation is not a provider outcomes study

Science & Co says it works only with state-licensed US compounding pharmacies, that every batch receives third-party purity and potency testing, and that patients can request a certificate of analysis for their prescription. Those are concrete documentation claims worth following up on. However, the consulted pages do not name the pharmacy assigned to an individual patient or independently substantiate each testing assertion. A requested certificate could help document a preparation, but it would not by itself establish clinical outcomes for this service.

The company also discloses that compounded drugs are not FDA approved or evaluated by FDA for safety, effectiveness or quality. FDA’s broader guidance says compounded preparations do not undergo its premarket review and recommends them when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone is not proof of clinical inequivalence. Equally, pharmacy licensing and testing claims do not convert a compounded preparation into an FDA-approved product.

That distinction is the focus of our guide to approved medicines and compounded preparations. FDA approval concerns a specific product, not Science & Co as a platform. Readers should request the exact formulation and pharmacy identity rather than infer them from a branded-looking page or familiar ingredient name. There is no basis in the consulted documentation to attribute semaglutide salt forms to this provider, and unanswered formulation questions should remain questions rather than allegations.

Sources: [14] [1]

Clinical research does not validate the entire storefront

The independent clinical context includes STEP 1, a randomized study of injected semaglutide, and SURMOUNT-1, a randomized study of injected tirzepatide. Both studied adults with obesity or overweight plus a weight-related condition or complication, without diabetes. Neither was a study of Science & Co. Their relevance is therefore specific: they establish findings about the studied interventions and populations, not measured performance of this platform, its compounded preparations, its oral listings or a proposed microdose service.

STEP 1 followed participants for 68 weeks, and SURMOUNT-1 for 72 weeks. Gastrointestinal tolerability and treatment discontinuation were part of the findings, not incidental details. Novo Nordisk funded STEP 1, and Eli Lilly funded SURMOUNT-1. Those features matter when evaluating evidence even without reproducing headline weight-change percentages. The studies also cannot be compared as though they were a randomized head-to-head comparison, and neither supplies an individualized prediction for a prospective Science & Co patient.

Science & Co’s terms say some imagery and before-and-after comparisons are illustrative and may be created or enhanced using computer techniques or artificial intelligence. Such material should not be treated as verified clinical evidence. The practical rule is the same as in our explanation of why a trial is not a telehealth performance report: ask what product, route, population and outcome a claim actually describes before allowing it to support a broader impression of the service.

Sources: [3] [4] [12]

Read the low prices alongside the unresolved payment terms

Compounded semaglutide injection is advertised from $59 per month on a 12-month plan, while compounded tirzepatide injection starts at $99 per month on a 12-month plan. Both pages advertise the same price across doses, no monthly membership fee and free shipping. The personalized GLP-1/GIP-1 injection also starts at $59 per month on a 12-month plan. These are conditional starting prices—not confirmed first charges or established month-to-month rates without a longer plan.

The semaglutide header also displays $149 and an advertised 60% saving; the tirzepatide header displays $199 and an advertised 50% saving. Separately, the homepage promotes 20% off the first month and a free online provider evaluation. The consulted documentation does not explain whether those promotions combine, what amount is collected initially, or how a 12-month plan’s price changes after early cancellation. It also does not establish specific prices for the branded products.

Subscriptions automatically charge at intervals disclosed at checkout. The terms say the total can include pharmacy charges, professional services and platform access, despite the marketing phrase “no monthly membership.” The FAQ describes cash payment and no insurance claim submission; the terms go further, prohibiting patients and participating entities from seeking or receiving public or private payer reimbursement for these services or products. HSA/FSA eligibility is described as general, with itemized receipts available, not guaranteed for every account or expense.

Sources: [14] [15] [16] [6] [9] [12]

Follow-up is described more clearly than its guaranteed cadence

The advertised plan includes clinician-reviewed assessment, treatment planning, clinically appropriate adjustments, secure messaging, scheduled check-ins, supplies, shipping and ongoing clinical monitoring. The FAQ says the same clinician stays with the patient month to month. These are substantive service claims, not merely access to a checkout page. However, the public material does not settle one contractual follow-up schedule: monthly check-ins appear in the marketing, while an illustrative interface describes weekly checks during the first eight weeks.

The phrase “24/7 support” is explained as the ability to message the care team at any time. It does not establish an immediate reply or a guaranteed response interval. The contact page identifies messaging through a member’s account as the fastest route, while support@science.co and 1 (844) 587-5747 are additional published contact paths. The site explicitly excludes medical emergencies and directs people to call 911 or go to the nearest emergency room.

This distinction matters because continued access and timely clinical attention are not identical promises. Before paying, readers can ask who reads messages, how clinical questions are escalated, when scheduled reviews occur and what happens if the regular clinician is unavailable. NIDDK emphasizes response and tolerability in ongoing care, not just prescription renewal. The company’s monitoring language is encouraging as a documented commitment, but it does not establish response performance or continuity in practice.

Sources: [9] [14] [5] [12] [2]

Shipping and cancellation leave important responsibilities to clarify

Science & Co advertises free monthly home delivery, but the consulted documentation does not establish a carrier, preparation interval, transit guarantee or detailed cold-chain procedure. The generic statement that medication is made by a licensed US pharmacy also does not resolve manufacturing questions for branded products whose pages name pharmaceutical manufacturers. The terms allow patients to request that an issued prescription be sent to a pharmacy of their choice, but do not establish how that choice changes the advertised package price.

FDA explicitly recommends not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy. The reviewed documentation does not establish Science & Co’s complete replacement process for that situation. Its terms also warn that pharmacy products may arrive without child-resistant packaging or containers. These are useful delivery and storage responsibilities to clarify before the first shipment, rather than treating free shipping as evidence that every fulfillment question has been answered.

For stopping future orders, Science & Co advertises no lock-in and no cancellation fee, with account-based or email requests at least 72 hours before the next processing date. Orders already prescribed, dispensed or shipped are not reversed. That is not a complete refund policy. Shipping & Returns content was not consulted, so refunds, damaged deliveries and replacements remain incompletely documented. The unresolved relationship between a 12-month discount and “no lock in” deserves a written explanation before payment.

Sources: [12] [14] [9] [11] [13] [1]

Questions & answers

Is Science & Co itself the medical practice or pharmacy?

No. Its terms describe Science and Co, Inc. as the technology platform, with independent professional entities responsible for care and independent pharmacies responsible for dispensing. The public documentation reviewed does not identify the specific organizations assigned to each patient. Ask for those names before enrollment so clinical, pharmacy and administrative questions can be directed to the responsible party.

Sources: [12]

Does the $59 semaglutide price establish my first payment?

No. It is a starting monthly price for compounded semaglutide injection on a 12-month plan. The documentation does not establish whether the initial collection is monthly, upfront or structured another way. It also leaves the relationship with the first-month promotion unclear. Request the actual first charge, recurring interval and cancellation-related price adjustments rather than treating the headline as a complete payment schedule.

Sources: [14] [6] [12]

Can I obtain the pharmacy’s testing documentation?

Science & Co says patients can request a certificate of analysis for their prescription and that every batch undergoes third-party purity and potency testing. This review did not independently verify those claims or examine a patient-specific certificate. Request the dispensing pharmacy’s identity along with the relevant document. Testing documentation should not be confused with FDA approval or a clinical study of the preparation.

Sources: [14] [1]

Can Science & Co bill insurance or provide a reimbursement receipt?

The FAQ describes cash payment and says the company does not submit claims to insurance, Medicare or Medicaid. More importantly, the terms prohibit seeking or receiving public or private payer reimbursement for products or services through the platform. An itemized receipt is offered for records, and HSA/FSA eligibility is described as general. Neither statement overrides the reimbursement restriction or guarantees account eligibility.

Sources: [9] [12]

How do I pause or cancel, and does that secure a refund?

Use the account or email support@science.co at least 72 hours before the next scheduled processing date. Science & Co says there is no cancellation fee, but cancellation does not reverse an order already prescribed, dispensed or shipped. It does not establish a refund entitlement. The complete refund policy and the financial consequences of leaving a discounted 12-month plan were not established in the consulted documentation.

Sources: [14] [9]

Does 24/7 support mean an immediate clinician response?

The page says members can message the care team at any time; it does not promise an immediate clinician reply or a guaranteed response deadline. Account messaging is described as the fastest member contact route. Ask how clinical concerns are triaged and when a clinician responds. The service is not for emergencies, which its contact page directs to 911 or an emergency room.

Sources: [14] [5]

Our assessment

Science & Co documents a recognizable GLP-1 access model: an online intake, independent prescribing, pharmacy fulfillment, messaging and ongoing monitoring, with both compounded and branded products advertised. Its disclosures about its platform role and compounded drugs are useful. Its testing and continuity claims are also specific enough to invite verification rather than vague reassurance. The remaining gaps are consequential: patient-specific pharmacy and clinical identities, exact personalized formulation, initial charges, early-cancellation economics and complete delivery remedies. Independent trials support conclusions about studied medicines, not Science & Co’s overall performance. A practical next step is to obtain a written product identification, assigned care and pharmacy details, complete payment schedule and applicable refund terms before deciding whether the documented service fits the reader’s priorities.

Visit Science & Co’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Science & Co Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the entity behind the promise

02The catalog contains several different evidence questions

03What the intake and prescribing process actually promises

04Quality documentation is not a provider outcomes study

05Clinical research does not validate the entire storefront

06Read the low prices alongside the unresolved payment terms

07Follow-up is described more clearly than its guaranteed cadence

08Shipping and cancellation leave important responsibilities to clarify